PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Overview Fund Activity
Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

50 hedge funds and large institutions have $61.1M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 18 reducing their positions, and 8 closing their positions.

Holders
50
Holders Change
-1
Holders Change %
-1.96%
% of All Funds
1.1%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
9
Increased
15
Reduced
18
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$540K
2
Wellington Management Group
2
Wellington Management Group
Massachusetts
$13.3M
3
Millennium Management
3
Millennium Management
New York
$326K
4
GTC
4
Ghost Tree Capital
New York
$1.65M
5
PTP
5
Platform Technology Partners
New York
$115K

Top Sellers

1
FCM
1
Farallon Capital Management
California
$280K
2
SAM
2
Sectoral Asset Management
Quebec, Canada
$0
3
PHP
3
Parkman Healthcare Partners
Connecticut
$0
4
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$1.96M
5
Goldman Sachs
5
Goldman Sachs
New York
$160K
Name Holding Trade Value Shares
Change 		Shares
Change %
ECM
51
ExodusPoint Capital Management
New York
– -$111K -18,160 Closed
FIA
52
FNY Investment Advisers
New York
– -$61K -10,000 Closed
Royal Bank of Canada
53
Royal Bank of Canada
Ontario, Canada
– -$18K -2,921 Closed
Bank of Montreal
54
Bank of Montreal
Ontario, Canada
– -$11K -1,748 Closed
BFEC
55
Benjamin F. Edwards & Company
Missouri
– -$6K -1,000 Closed
1 2
3